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Whole body cardiovascular magnetic
resonance imaging to stratify symptomatic
and asymptomatic atherosclerotic burden
in patients with isolated cardiovascular
disease
Jonathan R. Weir-McCall1,2,5*, Suzanne L. Duce1, Stephen J. Gandy2,3, Shona Z. Matthew1, Patricia Martin2,
Deirdre B. Cassidy1, Lynne McCormick1, Jill J. F. Belch1, Allan D. Struthers1, Helen M. Colhoun4
and J. Graeme Houston1,2
Abstract
Background: The aim of this study was to use whole body cardiovascular magnetic resonance imaging (WB CVMR)
to assess the heart and arterial network in a single examination, so as to describe the burden of atherosclerosis and
subclinical disease in participants with symptomatic single site vascular disease.
Methods: 64 patients with a history of symptomatic single site vascular disease (38 coronary artery disease (CAD), 9
cerebrovascular disease, 17 peripheral arterial disease (PAD)) underwent whole body angiogram and cardiac MR in
a 3 T scanner. The arterial tree was subdivided into 31 segments and each scored according to the degree of
stenosis. From this a standardised atheroma score (SAS) was calculated. Cine and late gadolinium enhancement
images of the left ventricle were obtained.
Results: Asymptomatic atherosclerotic disease with greater than 50 % stenosis in arteries other than that responsible
for their presenting complain was detected in 37 % of CAD, 33 % of cerebrovascular and 47 % of PAD patients.
Unrecognised myocardial infarcts were observed in 29 % of PAD patients. SAS was significantly higher in PAD
patients 24 (17.5-30.5) compared to CAD 4 (2–11.25) or cerebrovascular disease patients 6 (2-10) (ANCOVA p < 0.001).
Standardised atheroma score positively correlated with age (β 0.36 p = 0.002), smoking status (β 0.34 p = 0.002), and LV
mass (β -0.61 p = 0.001) on multiple linear regression.
Conclusion: WB CVMR is an effective method for the stratification of cardiovascular disease. The high prevalence of
asymptomatic arterial disease, and silent myocardial infarctions, particularly in the peripheral arterial disease group,
demonstrates the importance of a systematic approach to the assessment of cardiovascular disease.
Keywords: Whole body magnetic resonance angiography, Atherosclerosis, Coronary artery disease, Peripheral arterial
disease, Cerebrovascular disease, Atheroma burden
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Background
Atherosclerosis with subsequent plaque formation is the
underlying pathophysiological process in the leading
causes of morbidity and mortality in the western world
[1]. The widely distributed nature of atherosclerosis
across the body has been appreciated for decades [2],
however routine stratification or quantification of whole
body disease burden is not routinely performed. Multi-
modal imaging studies of patients presenting with cor-
onary artery disease [3, 4], cerebrovascular disease [5, 6]
and peripheral arterial disease [7–9], have shown a high
prevalence of atherosclerotic disease in other sites in
addition to the presenting disease. Multimodal studies
by their nature involved multiple examinations and typ-
ically require visits to different healthcare departments.
An alternative option is whole body cardiovascular mag-
netic resonance imaging (WB CVMR), which can assess
the heart and arterial network in a single examination,
has the advantages of being non-invasive and avoids ion-
ising radiation.
WB CVMR comprises of a suite of cardiac magnetic
resonance (CMR) and whole body MR angiography (WB-
MRA) sequences, allowing the systemic assessment of
whole body atheroma burden, with cardiac structure,
function and the detection of myocardial scarring, in a
single imaging session. Global atheroma burden has been
shown to correlate well with traditional cardiac risk fac-
tors, the prevalence of coronary artery disease and future
major adverse cardiovascular events [10–13]. Previous
studies have assessed the ability of WB-MRA to assess
extra-site disease in coronary arterial disease, peripheral
arterial disease and vasculitis [14–16]. However a direct
comparison of extra-site disease and atheroma burden be-
tween cardiovascular disease groups has not been previ-
ously conducted. The aim of the study was therefore to
determine the yield of WB CVMR in detecting asymp-
tomatic cardiovascular disease, at sites other than at the
clinically apparent location in different patient cohorts,
and to compare atheroma burden between the groups.
Methods
Ethics
The protocols were reviewed and approved by the East
of Scotland Research Ethics Committee and was con-
ducted in accordance with the Declaration of Helsinki.
All volunteers gave written informed consent to partici-
pate in this study.
Participants
Patients with isolated coronary, cerebrovascular or per-
ipheral vascular disease were identified from existing
clinical databases and from local cardiology, stroke, and
vascular clinics. Sixty-four participants with a prior diag-
nosis of single territory vascular disease attended MRI
appointments between March 2009 and December 2012.
The subjects were categorised based on their history of
cardiovascular disease; their demographics are sum-
marised in Table 1. Group 1 contained those with clin-
ical evidence of coronary artery disease (n = 38). Group
2 contained those who had had a cerebrovascular event
(n = 9). Group 3 contained those with clinical evidence
of peripheral arterial disease (n = 17).
Coronary arterial disease (Group 1) included non-
fatal acute myocardial infarction, hospitalised acute cor-
onary syndrome, resuscitated cardiac arrest (not attrib-
uted to a non CAD causes), coronary artery bypass
graft (CABG) or any other coronary revascularisation
procedure. Cerebrovascular disease (Group 2) inclusion
criteria were non-fatal strokes or transient ischemic at-
tacks (TIA) confirmed by a specialist stroke physician.
Peripheral arterial disease (Group 3) inclusion criteria
was ankle-brachial pressure index (ABPI) <0.9 with
intermittent claudication, walking distance of not more
than 200 yards, or abnormal toe systolic pressure. Vol-
unteers were excluded if they had a clinical history of
arterial disease at any site other than their primary
diagnosis location. Other exclusion criteria included the
possibility of metallic implants, history of claustropho-
bia, pregnancy, renal replacement therapy, end stage
renal disease, therapy for any chronic inflammatory dis-
ease, atrial fibrillation or malignancy.
Table 1 Demographics and clinical characteristics in the study
population
Group 1 Group 2 Group 3
CAD CVD PAD
Number 38 9 17
Male [%] 31 (81.6) 4 (44.4) 13 (76.5)
Age [years] 66.0 ± 8 61.2 ± 8 68.7 ± 10
Weight [kg] 87.2 ± 13 77.4 ± 12 89.7 ± 28
Height [m] 1.69 ± 0.1 1.64 ± 0.1 1.7 ± 0.1
BMI [kg/m2] 30.6 ± 4 28.7 ± 2 28.8 ± 4
Systolic BP [mmHg] 135 ± 15 132 ± 12 137 ± 14
Diastolic BP [mmHg] 76 ± 9 74 ± 8 78 ± 8
Hypertension 32 (84.2) 6 (66.7) 13 (76.5)
Antiplatelet 34 (89) 9 (100) 15 (88)
Antihypertensive 37 (97) 8 (89) 14 (82)
Statin prescription 30 (79) 8 (89) 16 (94)
Type 2 Diabetes 19 (50) 5 (55.6) 6 (35.3)
Non-Smokers 16 (42) 1 (11) 1 (6)
Former-Smokers 20 (53) 8 (89) 11 (65)
Smokers 2 (5) 0 (0) 5 (29)
Values expressed as Mean ± SD, or N (%)
BMI body mass index, BP blood pressure, CAD coronary artery disease, CVD
cerebrovascular disease, PAD peripheral arterial disease
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Magnetic resonance imaging
Images were acquired on a 32 RF receiver channel, 3
Tesla MRI scanner (Magnetom Trio, Siemens, Erlangen,
Germany) equipped with high-performance gradient sys-
tem and electrocardiograph (ECG)-gating. For whole
body coverage, a combination of six RF coils were used:
head matrix (12 elements); neck matrix (4 elements);
spine matrix (up to 24 elements); two body matrix (6
elements each); and peripheral angiography phased
array RF surface coils (16 elements. Subjects were
placed head first into the magnet bore and were exam-
ined in the supine position. Total scan time was of the
order of 45 min.
Whole body magnetic resonance angiography protocol
For localisation, four low-resolution images were acquired
from head to foot using gradient echo fast low angle shot
(FLASH) sequences with 500 mm field of view (FOV).
Whole body magnetic resonance angiography (WB-MRA)
images involved the acquisition of 4 overlapping 3D data
sets using a coronal spoiled FLASH (fast low angle shot)
sequence (see Table 2 for acquisition parameters). Four
anatomically distinct stations with field of view of 500 mm
were: head and thorax (station 1), thorax and abdomen
(station 2), abdomen and upper legs (stations 3) and lower
legs (station 4). These were positioned with an overlap of
at least 75 mm between each field of view. Anatomical
paired images were acquired pre- and post-contrast. A
standard dose of 25 ml gadoterate meglumine contrast
agent (Dotarem, Guerbet, Villepinte, France) was adminis-
tered by intravenous injection in the antecubital fossa in 2
separate boluses (10 ml and 15 ml respectively) using a
Spectris Solaris power injector (MedRad, Pittsburgh,
USA) at a rate of 1.5 ml/sec, each followed by a 20 ml
bolus of saline. For station 1 and 4 imaging, post-contrast
images were acquired after an injection of 10 ml of
0.5 mmol/ml gadoterate meglumine contrast agent. Sta-
tion 1 image acquisition commenced when the bolus of
contrast agent arrived at the top of the aortic arch in the
‘2D Care Bolus’ images (Siemens, Erlangen, Germany).
Station 4 image acquisition followed immediately after
this, with three consecutive volumes of station 4 acquired
to ensure that peak arterial enhancement was caught.
There was a delay before stations 2 and 3 image acquisi-
tion of at least 10 min to allow contrast washout and min-
imise venous contamination during the second injection
and image acquisition [17]. Post-contrast images were
acquired after an injection of 15 ml of 0.5 mmol/ml
gadoterate meglumine contrast agent, again followed by
a 20 ml saline bolus. Acquisition commenced once the
contrast agent bolus was seen in the descending aorta
in the coronal 2D Care Bolus image. Station 3 imaging
commenced immediately after the completion of the
acquisition of station 2.
Cardiac magnetic resonance (CMR) protocols
Cardiac magnetic resonance (CMR) imaging utilised a
spine matrix and six-element body array matrix RF coils.
Left ventricular assessment involved the acquisition of
short axis, multi-slice 2D images from the atrio-ventricular
ring to the apex using a CINE TrueFISP sequence with
retrospective ECG-gating, with repeated end-expiratory
breath-holds (Table 2). The slice thickness was 6 mm
and inter-slice gap was 4 mm. Ten minutes after the in-
jection of the first dose of contrast agent, the ECG-
gated, breath-hold, end-diastole, short-axis, multi-slice
late gadolinium enhanced (LGE) CMR images were ac-
quired using a 2D phase sensitive inversion recovery
(PSIR) sequence (Table 2).
WB-MRA image analysis
Researchers were blind to the participants’ clinical history
during image analysis. The 3D WB-MRA datasets were
viewed offline as source images using both multi-planar
reconstruction (MPR) and maximum intensity projections
(MIP) (Carestream PACS Client Suite Version 10.1 sp1,
Rochester, NY, USA) by a radiologist with experience of
reporting over 400 whole body magnetic resonance angio-
grams. Based on previous pilot work, the arterial network
was divided into 31 vessel segments extending from the
internal and external carotid arteries to the trifurcation
vessels of the lower limb (Fig. 1). Each arterial segment
was scored according to maximal luminal stenosis within
the vessel lumen. Categorical MRA scores from 0-4 were
Table 2 Imaging parameters for MRI sequences used for the combined CMR and WB-MRA protocol
Location Sequence Plane TR (ms) TE (ms) Flip Angle (0) Pixel size (mm) Slice thickness (mm)
WB-MRA Station 1 FLASH Coronal 2.68 1 19 1.1x1 1.1
WB-MRA Station 2 FLASH Coronal 2.6 0.96 16 1.3x1.1 1.3
WB-MRA Station 3 FLASH Coronal 3.47 1.21 37 1.5x1 1.4
WB-MRA Station 4 FLASH Coronal 2.61 0.96 22 1.2x1.1 1
LVA Heart LV TrueFISP Short axis 3.40 1.48 50-60 1.9x1.4 6
LGE-CMR Heart LV PSIR Short axis 846.4/5.21 1.99 20 1.9x1.4 6
WB-MRA whole body magnetic resonance angiography, LVA left ventricular analysis, LGE-CMR Late gadolinium enhanced cardiac magnetic resonance images, TR
repetition time, TE echo time
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allocated to each vessel segment, where 0 = healthy seg-
ment with no stenosis, 1 = <50 % stenosis, 2 = 51-70 %
stenosis, 3 = 71-99 % stenosis, 4 = vessel occlusion. For
each participant, the ‘standardised atheroma score’ (SAS)
was calculated using equation [1] where n is the number
of diagnostic segments [18].
SAS ¼ Σ MRA scores
n
 
 4
 
 100 ð1Þ
The 31 vessel segments were subdivided into 5 ana-
tomical territories: (i) the head and neck arteries, (ii) the
aorta, (iii) the abdominal arteries, (iv) the ilio-femoral ar-
teries and (v) the run off arteries in the lower limbs
(Fig. 1). Regional standardised atheroma scores were cal-
culated for each anatomical territory. For each patient
the individual vessel segments that had MRA scores of 3
or 4 were noted, with the number of vessels with sten-
osis greater than 70 % being counted and their location
recorded, as luminal narrowing of greater than 70 % is
considered clinically significant. In addition a moderate
stenosis assessment recorded the number and location
of vessel segments that had MRA scores equal to 2 (50-
70 % stenosis), in a similar manner to that of the severe
stenosis assessment.
(ii) CMR image analysis
Left ventricular analysis images were analysed offline
using Argus software (Siemens, Erlangen, Germany) by
two experienced CMR researchers. The manual 3D
digital segmentation involved tracing endocardial and
epicardial contours on the short-axis left ventricle im-
ages at end-diastolic and end-systolic phases of the car-
diac cycle. Papillary muscles were treated as part of the
blood pool volume unless they were indistinguishable
from the myocardial wall, and then they were assigned
as left ventricle muscle. The left ventricular mass (LVM),
stroke volume (SV), ejection fraction (EF), end-diastolic
Fig. 1 Whole body magnetic resonance angiogram showing the acquisition stations 1 to 4 (left of image) and the 5 arterial territories (right of image).
The 31 vessel segments are listed (far right box)
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(EDV) and end-systolic volumes (ESV) were determined
using an algorithm based on the Simpson rule [19]. Re-
sults were normalised to body surface area. Left ven-
tricular hypertrophy was defined as an indexed LVM
above the normal range for sex [19]. Late gadolinium
enhanced images of the left ventricle were inspected for
evidence of myocardial signal enhancement using a
Carestream PACS workstation (Rochester, NY, USA).
The location was recorded according to the AHA 17
segment model [20]. Delayed enhancement was defined
as <50 % or >50 % wall thickness according to the max-
imum depth of delayed enhancement in any segment.
Statistical methods
Descriptive statistics were used for the analysis of the
demographic and clinical features of the cohorts with data
expressed as mean ± standard deviation (sd) for normally
distributed data, and median (interquartile range) for non-
normal distributed data. Normality tests were performed;
if the test failed, where possible standard transformations
such as square root, reciprocal or logarithmic transforms
were used to generate a Gaussian distribution. To test the
null hypothesis to determine if samples originated from
the same distribution, one-way analysis of variance
(ANOVA) with the Bonferroni post hoc adjustment was
used for the parametric data, and Kruskal–Wallis ANOVA
by ranks was used for the non-parametric data. ANCOVA
was performed to confirm differences between the groups
with the WB-SAS as the dependant variable. MANCOVA
was used to determine the relations of the LV metrics to
the demographic data with the LV metrics entered as the
dependant variables. Pearson correlation coefficients be-
tween WB-SAS, LVA and population demographic met-
rics were reported. All variables with a p-value <0.3 on
univariate analysis were entered into a multivariate regres-
sion analysis with the WB-SAS as the dependent variable
and the remainder as independent variables. All data were
analysed using SPSS statistical package (version 21.0, SPSS
Inc. Chicago, Illinois). Significance was assumed when p <
0.05. A local statistician provided statistical support.
Results
CMR and whole body MRA images were acquired from
64 participants (75 % male, age 66.1 ± 8.5) with single
site cardiovascular disease. There were no statistically
significant differences in the demographic metrics be-
tween each of the diseased groups (Table 1), except for
smoking status with significantly more people in the
PAD group being current smokers than in either the
CAD or cerebrovascular groups.
In the WB-MRA analysis, 1978 of the 1984 vessel seg-
ments (99.7 %) were interpretable. 6 segments in 4 of
the 64 examinations were rated as ‘non-diagnostic’ due
to movement artefact or incomplete vessel visualisation.
619 (31.3 %) of the 1978 arterial segments had evidence
of luminal narrowing: 453 (22.9 %) had stenosis below
50 %, 61 (3.1 %) had stenosis between 50-70 %, 63
(3.2 %) had stenosis between 70-90 %, and 42 (2.1 %)
had complete occlusion.
The PAD group had the highest whole body standardised
atheroma score (WB-SAS) of 24.8 ± 9.9 and the CAD
group had the lowest WB-SAS of 7.0 ± 6.2. The WB-SAS
of the PAD patients was statistically significantly higher
than those of either the CAD or cerebrovascular disease
patients (ANOVA test: P ≤ 0.001). Differences between the
groups persisted on ANCOVA (F = 15.18, p < 0.001), ac-
counting for age, gender, smoking status, blood pressure,
BMI and statin prescription. There was no significant dif-
ference in the WB-SAS between the CAD and cerebrovas-
cular disease groups. Across all 5 anatomical territories,
the PAD subjects’ regional SAS were consistently higher
compared to either the CAD or cerebrovascular groups’
scores (Table 3). There were no statistically significant dif-
ferences between any of the regional SAS of CAD and
cerebrovascular group. On univariate analysis, there were
positive correlations of SAS with age (r = 0.37 P =
0.002), smoking status (r = 0.397 P = 0.002), LV ejection
fraction (r = -0.26 P = 0.034) and LV mass (r = -0.42 P =
0.001) and a trend towards an association with diastolic
blood pressure (r = -0.23 P = 0.052) (Table 4). On multi-
variate analysis, age (β 0.36 p = 0.002), smoking status
(β 0.34 p = 0.002), and LV mass (β -0.61 p = 0.001) con-
tinued to demonstrate a significant association with
WB-SAS.
For each patient, the extent of stenosis was further in-
vestigated by counting the number of vessel segments
that had either (a) severe stenosis with MRA score of 3
or 4 (associated with luminal narrowing of greater than
70 %) or (b) moderate stenosis with MRA score of 2 (as-
sociated with luminal narrowing of between 50 and
70 %). The results are summarised in Table 5. 100 % of
PAD patients have severe stenosis detectable in at least
one arterial vessel, with the ilio-femoral arteries being
most affected. A third of the CAD patients had severe
stenosis present in their MRA images, with the run off
arteries most commonly affected (18.4 % of patients),
while severe arterial stenosis was detected in only 22 %
of the cerebrovascular patients. With luminal narrowing
of greater than 70 % considered clinically significant, this
analysis is useful for screening patients and highlighting
those who require follow-up investigations.
The left ventricular assessment (Table 3) revealed that
the PAD group have the largest mean left ventricular mass
(LVM), end-diastolic (EDV), end-systolic volume (ESV),
cardiac ejection fraction (EF) and stroke volume (SV), and
these differences reached statistical significance for the
LVM, EDV and SV values (ANOVA P ≤ 0.007). These dif-
ferences persisted on MANCOVA (F = 8.87, p = 0.001 for
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LVM, F = 3.27, p = 0.047 for EDV and F = 4.43, p = 0.018
for LVM). The differences between the CAD and cere-
brovascular disease cohorts were relatively small and
did not reach statistical significance. Left ventricular
hypertrophy was detected in 16 % of the study popula-
tion, while impaired left ventricular systolic function
was present in 13 %.
Late gadolinium enhancement (LGE) was observed in
21 (32.8 %) of the 64 subjects. All subjects with LGE had
scarring in a subendocardial location with a territorial dis-
tribution typical of an ischaemic aetiology. The majority of
the enhancement occurred in the CAD group, with 16
(42.1 %) CAD participants displaying evidence of myocar-
dial scarring, affecting a total of 91 AHA segments. No
myocardial LGE was observed in the cerebrovascular dis-
ease group images. Five (29.4 %) of the PAD group had
evidence of unrecognised myocardial infarction (UMI), af-
fecting a total of 21 AHA segments (See Figure 2). UMIs
tended to occur in the inferior wall with 9/21 UMIs occur-
ring in the inferior segments, with the second most com-
mon location being the inferoseptal segment with 4/21
UMIs occurring in this region. Recognised MIs demon-
strated no territorial predominance. UMIs were smaller,
involving an average of 4.2 AHA segments, compared
with 6.1 AHA segments in the recognised MI group. 40 %
of UMIs involved less than 50 % of the myocardial thick-
ness in the affected segments while the remaining 60 % in-
volved greater than 50 % of the myocardial thickness. In
comparison, 73 % of recognised MIs involved >50 % of
the myocardial thickness. No correlation was observed be-
tween WB-SAS and either the presence or the severity of
the late gadolinium myocardial enhancement.
Discussion
We have shown that whole body cardiovascular MRI is a
feasible solution to stratify the extent of atherosclerosis
in arteries and the extent of cardiac dysfunction and
myocardial scarring in a 45-min exam. This is also the
first study to show a positive correlation between the
Table 3 Whole body cardiovascular magnetic resonance imaging (WB CVMR) data for each group including magnetic resonance
angiography (MRA) scores, standardised stenosis scores (SAS), left ventricular analysis (LVA) and left ventricular late gadolinium
enhancement (LGE) results
Group 1 Group 2 Group 3
CAD CVD PAD
WB-SAS 4 (2–11.25) 6 (2-10) 24 (17.5-30.5)
Head/Neck-SAS 2.8 (0–5.6) 8.3 (1.4–9.7) 19.4 (9.7-25)
Aorta-SAS 8.3 (0–16.7) 8.3 (8.3-12.5) 8.3 (8.3-16.7)
Abdomen-SAS 8.3 (0–10) 0 (0–5) 20 (5-27.5)
Ilio-Femoral-SAS 6.25 (0–20.8) 4.2 (2.1–14.6) 37.5 (27.1-52.1)
Run Off-SAS 0 (0–10.2) 0 (0–18.7) 31.3 (11-48.5)
LVM (g/m2) 59.1 (54.1–64.5) 53.4 (47.4–71.1) 105.7 (67.8-124.5)
EDV (ml/m2) 74.7 ± 18.8 72.4 ± 15.2 104.1 ± 34.9
ESV (ml/m2) 25.3 (18.3–29.7) 22.4 (17.8–35.8) 33.8 (22.8-42.8)
EF (%) 64.5 ± 9.8 64.7 ± 13.4 66.4 ± 11.8
SV (ml/m2) 46.8 (40.4–52) 46 (40.2–52.7) 73.7 (39.4-92.7)
LGE 16 (42.1 %) 0 (0 %) 5 (29.4 %)
Values expressed as Mean ± SD, Median (Interquartile range) or N (%)
CAD coronary artery disease, CVD cerebrovascular disease, PAD peripheral arterial disease, SAS standardised atheroma score, WB whole body, LVM indexed left
ventricular mass, EDV indexed end diastolic volume, ESV indexed end systolic volume, EF ejection fraction, SV indexed stroke volume, LGE Late gadolinium enhancement
Table 4 Correlation of whole body standardised atheroma
score with demographic and left ventricular parameters
Pearson correlation P-value
Age 0.461 <0.001
Gender -0.19 0.091
Systolic BP 0.19 0.095
Diastolic BP -0.23 0.052
BMI -0.22 0.06
Hypertension 0.13 0.18
History of Smoking 0.4 0.002
T2DM 0.05 0.37
Statins 0.008 0.48
Left ventricular metrics
LV End diastolic volume 0.11 0.22
LV End systolic volume 0.17 0.11
LV stroke volume -0.18 0.11
Ejection fraction -0.26 0.03
LV mass -0.42 0.001
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whole body atherosclerotic stenotic burden and left ven-
tricular mass.
Stratified medicine has become a topic of increasing
importance [21, 22]. This is as important in cardiovascu-
lar disease as it is in cancer, and requires accurate defin-
ition and quantification of disease. This is especially
important given findings that polyvascular disease is
associated with significantly higher rates for major ad-
verse cardiovascular events than in single site vascular
disease [23]. In our study we have demonstrated the
ability of WB-MRA to stratify and quantify atheroscler-
otic burden throughout the body. Significant undetected
arterial stenoses were found to be present in multiple
sites in all disease groups. We found a 37 % prevalence
Table 5 The percentage of patients in each group that have at least one vessel segments with (a) severe stenosis (MRA score = 3 or
4) and (b) moderate stenosis (MRA score = 2) for the different anatomical territories. The bracketed number is the total number of
vessel segments with the relevant degree of stenosis
Anatomical
Territories
(a) Severe stenosis (b) Moderate stenosis
Group 1 Group 2 Group 3 Group 1 Group 2 Group 3
CAD CVD PAD CAD CVD PAD
Whole body (%) 34.2 (26) 22.2 (6) 100 (73) 37 (21) 56 (6) 88 (34)
Head/Neck (%) 5.3 (4) 0 (0) 29.4 (8) 11 (4) 33 (3) 29 (7)
Aorta (%) 0 (0) 0 (0) 5.9 (1) 3 (1) 0 (0) 6 (1)
Abdomen (%) 7.9 (4) 11.1 (1) 52.9 (11) 18 (7) 0 (0) 12 (2)
Ilio-Femoral (%) 10.5 (6) 0 (0) 76 (28) 8 (5) 11 (1) 59 (15)
Run off (%) 18.4 (12) 22.2 (5) 58.8 (25) 8 (4) 22 (2) 41 (9)
CAD coronary artery disease, CVD cerebrovascular disease, PAD peripheral arterial disease
Fig. 2 a Whole body angiogram of a peripheral arterial disease patient. b Sagittal MIP (maximum intensity projection) of the bifurcation of the
left carotid artery showing >50 % stenosis of the internal carotid artery (arrow head). c Coronal MIP of the renal arteries showing a normal right
renal artery but a >70 % stenosis of the left renal artery (arrow head). d Coronal MIP showing a long segment occlusion of the left superficial
femoral artery (arrow) with extensive collateral formation (arrow heads) with reformation distally. e Short axis late gadolinium enhancement
showing a large unrecognised myocardial infarct (arrow head). f 4 chamber view of the heart showing normal dimensions of the ventricles
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of extra-coronary arterial disease in CAD. This is lower
than the 50 % reported in one study although this latter
study did not exclude patients with known extra-
coronary disease [16]. It is also lower than the 55 % re-
ported in a more recent study [12], although this was
performed at 1.5 T with a lower spatial resolution than
obtained in the current study, thus the improved arterial
definition may have led to a more accurate quantifica-
tion of the degree of stenosis due to improved spatial
resolution found at 3 T. We found that 33 % of cerebro-
vascular disease patients had significant disease outwith
the head and neck. This is significantly lower than that
reported by Paraskevas et al. [5], however their study
only looked at patients with known unilateral internal
carotid artery occlusion which is at the extreme end of
the carotid disease spectrum, while our study used prior
cerebrovascular events as inclusion criteria. Our PAD
cohort demonstrated significant disease above the level
of the abdominal aortic bifurcation in 47 % which is
slightly higher than that previously reported on WB-
MRA [15].
The standardised atheroma score was significantly
higher in the peripheral arterial disease group than ei-
ther the cerebrovascular or the coronary arterial disease
group. Previous epidemiological studies have shown that
patients with PAD have a 33 % higher composite risk of
CV death, myocardial infarction, stroke, or hospitalisation
for atherothrombotic event(s) than either cerebrovascular
or coronary arterial disease groups [24]. As well as the in-
trinsic risk of arterial stenosis, part of the causative mech-
anism may be the effect the atherosclerotic burden has on
the heart. We have shown for the first time the association
between whole body arterial atheroma burden and left
ventricular mass, which is known to be strongly associated
with future cardiovascular events [25]. This may be due to
the stiffening nature of the atherosclerosis on the arteries,
as total atheroma burden has been shown to correlate
with arterial stiffness, [26] which in turn is associated with
left ventricular hypertrophy [27]. Given that both left ven-
tricular mass and atheroma burden are associated with in-
creased future risk of cardiac events, further work is
required to extricate the interaction between these mea-
sures, to ascertain whether these need to be targeted indi-
vidually, or whether there is a single linking aetiology
which can be targeted.
Unrecognised myocardial infarctions are present in
29.4 % of patients with peripheral arterial disease. The rate
in peripheral arterial disease patients is significantly higher
than the 6 % reported in a previous PAD population using
ECG and echocardiography during pre-operative work-up
[28], or the 14 % reported in a series of patients undergo-
ing pre-operative coronary angiography screening [29].
However ECG has been shown to only detect 6-29 % of
unrecognised myocardial infarcts revealed on late
gadolinium enhancement [30, 31]. Our observed inci-
dence is closer to that expected from a previous study
looking at whole body cardiovascular MR in a population
cohort study which showed rates of unrecognised myocar-
dial infarction in 19.7 % of 70 year olds and 30 % in 75 year
olds [30, 32]. That the prevalence in the PAD population
was on par with a 75 year old cohort despite having a
mean age of 68 is in keeping with the higher prevalence of
risks factors in our population, although a recent study
has called into question the link between unrecognised
myocardial infarctions and traditional risk factors [33].
None of the patients with cerebrovascular disease had
evidence of unrecognised myocardial infarcts. This is
surprising given the results of previous studies showing
unrecognised myocardial infarcts in 32 %-52 % of pa-
tients but may be due to the small numbers of this
group in the current study.
Recognition of unrecognised myocardial infarction is
important as these have the same prognostic implica-
tions as recognised myocardial infarcts [34]. Further-
more these patients respond well to both conventional
secondary prevention medication and percutaneous cor-
onary intervention [35–37].
It could be argued that since patients with clinically ap-
parent cardiovascular disease in one site will result in pa-
tients being treated for atherosclerotic risk factors that
further information about disease elsewhere is superflu-
ous. However this ignores several factors. Despite our
study showing comparable rates of statin prescriptions be-
tween the different groups, a previous population study
has shown that community prescription of risk modifying
agents is markedly different between disease groups, with
fewer patients with PAD being prescribed statins and anti-
platelet agents compared with stroke or coronary artery
disease groups [38]. This suggests poor appreciation of
the extensive disease present elsewhere in the body, in-
deed, in our study the PAD population had the most ex-
tensive extra-primary site disease. The second is the
additional prognostic information this provides. Multisite
disease is associated with a significantly raised risk of fu-
ture major adverse cardiac and cerebrovascular events
(MACCE) compared with single site disease, and had a
greater detrimental effect on future prognosis than the
presence of diabetes [23, 38]. While these studies have fo-
cused on symptomatic disease, the significance of asymp-
tomatic disease is supported by recent studies showing
increased risk of MACCE in patients with higher global
atherosclerotic burden on whole body MR angiography
[10, 11]. Thus patients with polyvascular disease may war-
rant more intensive management and follow-up as well as
being ideal candidates for future novel therapeutic agents
[24]. For those being referred for a clinical MRA of a spe-
cific vascular territory, extension of this to a whole body
cardiovascular MR would be a logical step, and indeed the
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added cost of extending a clinically indicated MRA to in-
clude the rest of the body is small when considered in re-
lation to the high cost of the baseline exam, and in a
peripheral arterial disease population has been shown to
be cost effective due to its reductions in requirements for
other imaging investigations (such as echocardiography
and carotid Doppler) and alterations in patient manage-
ment, although other cardiovascular disease cohorts have
still to be assessed [39].
The limitations of the current study are: The study
groups are unequal in size with a relatively small num-
ber of cerebrovascular patients and large number of cor-
onary arterial disease. In addition the cerebrovascular
group demonstrates a disproportionate number of fe-
males which could bias the results, however we demon-
strated no significant correlation between SAS and sex,
and accounting for sex using an analysis of covariance
did not change the results. An intrinsic limitation of
WB-MRA is its ability to only provide information on
the prevalence of stenotic atherosclerosis, and will thus
miss the earliest stages of the disease including vessel
stiffening and remodelling. Additionally, while the prog-
nostic effect of symptomatic multisite atherosclerosis is
known, the effect of asymptomatic multisite disease still
requires further work to elucidate.
Conclusion
WB CVMR is an effective method for the stratification
of cardiovascular disease. The high prevalence of
asymptomatic arterial disease, and silent myocardial in-
farctions, particularly in the peripheral arterial disease
group, demonstrates the importance of a systematic ap-
proach to the assessment of cardiovascular disease.
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